Influential Drug Cost-Effectiveness Organization Endorses Partially Lifting 340B Orphan Drug Exclusion

Policymakers should consider narrowing the 340B orphan drug exemption, ICER said today in a new report.

The exclusion of 340B pricing for some hospitals on drugs to treat orphan conditions and diseases could be partially eliminated to slow “the rapid growth in approved rare disease treatments” and “their cumulative affordability to the health system,” an influential

Read More »

CMS Projects that Drug Spending and Drug Prices Will Keep Rising Through 2030

CMS predicts that U.S. retail prescription drug spending will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.

Federal actuaries predict retail prescription drug spending in the United States will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.

Please Login or Become a Paid Subscriber to

Read More »

Conservative Massachusetts Think Tank Slams State’s 340B Hospitals over Charity Care and Calls for Reform

Charity care at five Massachusetts hospital groups declined at a time that 340B sales to the hospitals were rising, a new report by a conservative state think tank says. The state hospital association says the report distorts the 340B program.

Charity care has been declining significantly in some Massachusetts hospital systems, raising “a significant policy issue for the 340B program,” a free-market-oriented Massachusetts think tank whose donors include pharmaceutical manufacturers says in a new report.

Please

Read More »

Economists Say 340B Hospital and Grantee Entities Use Contract Pharmacy for Different Reasons

A new study finds that contract pharmacy growth patterns differ between 340B hospital and non-hospital entities.

Contract pharmacy growth patterns differ between 340B hospital and non-hospital entities, suggesting they may use 340B differently and should be subject to different 340B rules, new research concludes.

Please Login or Become a Paid Subscriber to

Read More »

New JAMA Study Casts Doubt on CMS Reason for Cutting Hospitals’ Medicare Part B Payments for 340B Drugs

New research “raises doubt” about a major CMS reason for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third.

New research published in JAMA Network Open “raises doubt” about a major U.S. Centers for Medicare & Medicaid Services (CMS) justification for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third, the study’s

Read More »

Democratic Senator’s Illness Stalls Action on Drug Pricing Indefinitely

Sen. Ben Ray Lujan's (D-N.M.) recent stroke and absence makes it even less likely that Congress will pass Democratic drug pricing legislation any time soon.

Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.

Please

Read More »

ICER Says Four Drugs Are Cost-Effective in Keeping COVID-19 Patients Out of Hospitals

The Institute for Clinical and Economic Review has tentatively concluded that four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.

The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.

Please Login or Become a Paid Subscriber to

Read More »

Hospitals Taking Heavy Losses Due to Drug Company Limits on 340B Pricing, Survey Says

340B Health says a new survey of its members shows 340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies.

340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies, according to a new survey from hospital group 340B Health.

Please Login or Become a Paid

Read More »

PhRMA Says More than Half of Pharmacy and Provider Profits on Brand Drug Sales Come Through 340B

PhRMA says 52% of U.S. pharmacies and health care providers profits' from reimbursement for administering brand-name prescription drugs now comes through participation in the 340B program. The AHA calls the finding an example of drug companies deflecting attention away from the high prices they set.

More than half (52%) of the $81 billion that U.S. pharmacies and health care providers collected in 2020 in reimbursement from payers for brand-name prescription drugs came through pharmacy and provider participation in the 340B program, up from 14% of

Read More »

Is There a New 340B Stakeholder Group for Pharma Companies?

A new infographic by a drug industry consultant indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.

A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.

Please Login or Become a

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report